Research / TCBX / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-26-206643 Bank
Sequential deposit growth 100th Own-history percentile · N=17
Evidence method Sequential · gp.financial.deposits
23.52% · CORE · VALID
Net-income growth 14th Own-history percentile · N=14
Evidence method Yoy · gp.fundamentals.net_income
20.45% · CORE · VALID
Cash and equivalents 100th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.cash
$425.2M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 19 states Self-history eligible
Dec 31, 2021 0/3 normalized Level 3 Mar 31, 2022 0/3 normalized Level 3 Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 0/5 normalized Level 3 Dec 31, 2022 0/5 normalized Level 3 Mar 31, 2023 0/5 normalized Level 3 Jun 30, 2023 0/5 normalized Level 3 Sep 30, 2023 1/5 normalized Level 3 Dec 31, 2023 3/5 normalized Level 3 Mar 31, 2024 3/5 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 3/3 normalized Level 3 Dec 31, 2024 3/3 normalized Level 3 Mar 31, 2025 3/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 4 Period transition
What moved in the state? Deposit Growth Increased
Previous 5.81%
Current 23.52%
Delta 17.71% Earnings Growth Decreased
Previous 39.06%
Current 20.45%
Delta -18.61% Liquidity Increased
Previous $175.2M
Current $425.2M
Delta $250.0M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.